CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

Recent Videos


ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide

Vlado Perkovic,

Watch time: 5m 40s


Importance of Testing for CKD Among Patients With Type 2 Diabetes

Pam Taub, Nikolaus Marx,

Watch time: 10m 51s


ECO 24: The STEP 10 Trial

Barbara McGowan,

Watch time: 8m 28s


ECO 24: EASL-EASD-EASO Practice Guidelines for MAFLD

Sven M Francque,

Watch time: 10m 28s


HFA 24 Late-Breaker Wrap Up with Dr Van Spall & Dr Petrie

Harriette Van Spall, Mark Petrie,

Watch time: 15m 26s


HFA 24: The FINE-HEART Study

Muthiah Vaduganathan,

Watch time: 4m 40s